MSH2 and Lynch syndrome: The International Cancer of the Pancreas Screening (CAPS) Consortium summit in April 2018 identified potential candidates for screening, as follows: (1) individuals with germline mutations in LKB/STK11 (Peutz–Jeghers syndrome) and CDKN2A (FAMMM) regardless of family history; (2) individuals with germline mutations in BRCA2, PALB2, ATM, and MLH1/MSH2/MSH6 (Lynch syndrome) with at least one affected FDR; and (3) individuals with at least two affected relatives on the same side of the family, of whom at least one is an FDR regardless of gene mutation status.